Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab), administe...
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag™ (nivolumab and relatlimab-rmbw) for the adjuvant...
Pfizer Inc. announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP)...
DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensi...
A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now approved for use ...
Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment o...
Bristol Myers Squibb announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi® (lisocabtagene maraleucel) in adult patients with rel...
Partner Therapeutics, Inc. (PTx), a private, fully-integrated biotechnology company announced that the New England Journal of Medicine (NEJ...
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce the completion of patient enrollment in the global Phase III clini...
AstraZeneca’s Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of adults ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a...
HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone receptors for estrogen and/or progeste...
Bristol Myers Squibb (NYSE: BMY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® ant...
© 2025 Biopharma Boardroom. All Rights Reserved.
